quantbrah

Trading the situation. AI turns X posts into trackable portfolios. Not financial advice.

Lilly’s retatrutide data points to continued obesity-drug leadership and share gains versus current GLP-1 incumbents

The post makes a direct, forward-looking claim that Lilly’s Phase 3 retatrutide results are so strong that the drug will surpass tirzepatide and semaglutide and become the leading obesity therapy. The cleanest market translation is a concentrated long in Eli Lilly, with a smaller short in Novo Nordisk as the most exposed incumbent whose semaglutide franchise risks relative competitive pressure.

ALL TIME RETURN +6.51%
S&P 500 +1.24%
VS S&P 500 +5.27%
Return -5.74%
S&P 500 +0.89%
VS S&P 500 -6.63%
Best performer NVO +1.09%
Portfolio S&P 500 AS OF JUL 14, 8:40 PM
  • LLY Long
    Performance +10.79%
    Current weight 80.03%

    Description Retatrutide Phase 3 success strengthens Lilly’s obesity franchise and future market-share leadership.

  • NVO Short
    Performance -10.62%
    Current weight 19.97%

    Description Semaglutide franchise faces relative share and perception pressure from stronger Lilly data.

Created
Last checked
Positions
2

Not financial advice. Hypothetical portfolio for informational purposes only. Returns are approximate and do not account for splits, dividends, borrow costs, or financing. Privacy notice.